PT  - JOURNAL ARTICLE
AU  - Möhler, H.
AU  - Fritschy, J. M.
AU  - Rudolph, U.
TI  - A New Benzodiazepine Pharmacology
AID  - 10.1124/jpet.300.1.2
DP  - 2002 Jan 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 2--8
VI  - 300
IP  - 1
4099  - http://jpet.aspetjournals.org/content/300/1/2.short
4100  - http://jpet.aspetjournals.org/content/300/1/2.full
SO  - J Pharmacol Exp Ther2002 Jan 01; 300
AB  - Classical benzodiazepine drugs are in wide clinical use as anxiolytics, hypnotics, anticonvulsants, and muscle relaxants. They act by enhancing the γ-aminobutyric acidA (GABAA) receptor function in the central nervous system. The pharmacological relevance of the multitude of structurally diverse GABAAreceptor subtypes has only recently been identified. Based on an in vivo point mutation strategy, α1-GABAAreceptors were found to mediate sedation, anterograde amnesia, and part of the seizure protection, whereas α2-GABAAreceptors, but not α3-receptors, mediate anxiolysis. Rational drug targeting to specific receptor subtypes has now become possible. Only restricted neuronal networks will be modulated by the new subtype-selective drugs. Promising new anxiolytics have already been developed. A new pharmacology of the benzodiazepine site is on the horizon. GABAγ-aminobutyric acidmIPSCminiature inhibitory postsynaptic currents